This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Michael G. Dunn, MD, PhD
The Genesee Hospital 224 Alexander St Rochester, NY 14607

Arch Neurol. 1991;48(6):570.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The post-polio syndrome (PPS) has received increased attention in recent years. This is a chronic slowly progressive condition with cardinal features consisting of weakness, atrophy, aches, cramps, and fatigue decades after the initial infection. Fatigue may be an incapacitating feature of this illness.

Amantadine has been found to be beneficial in the fatigue of multiple sclerosis.^1,2 The basis for this is uncertain. Amantadine also possesses antiviral and antiparkinsonian effects.

Over the last year an open study of amantadine (100 mg two times a day) given for the fatigue of PPS has been carried out in nine patients. All patients had PPS as diagnosed by a combination of accepted criteria, including history, physical examination, and electrodiagnostic testing, where applicable. The study used a 2-week control period with daily self-rating of fatigue on a subjective 0 (no fatigue) to 10 (incapacitating fatigue) scale. Treatment with amantadine (100 mg . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?